Nyxoah Provides Update on FDA Approvable Letter for Genio System
Nyxoah Provides Update on FDA Approvable Letter for Genio System
Expects to meet final FDA requirements for full PMA approval in the second quarter
Mont-Saint-Guibert, Belgium – April 8, 2025, 07:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)
('Nyxoah' or the 'Company'), which develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced an update on the FDA approval process for the Genio system.
On March 26, 2025, the Company announced that the U.S. Food and Drug Administration (FDA) issued an Approvable Letter regarding the Company's Pre-Market Approval (PMA) application for the Genio® system.
The Approvable Letter means that Nyxoah's application for marketing the device in the United States substantially meets the requirements of the Federal Food, Drug and Cosmetic Act and the FDA's PMA implementing regulations codified at 21 C.F.R. Part 814, and the FDA will approve the application subject to satisfactory completion of a manufacturing facilities, methods and controls review. FDA has accepted all other data provided with the PMA submission, including most importantly the clinical study that demonstrates the safety and effectiveness of the Genio® system.
Nyxoah is actively addressing one remaining item before FDA approval may be granted which is the validation of one process used with a component of the Genio system at its U.S. manufacturing site. The Company is confident that it will be able to successfully complete this validation in the near term. As such, Nyxoah anticipates that its application could potentially be approved in the second quarter and intends to provide an update on the review process on its first quarter 2025 earnings call to be held in May.
'We are pleased to share that the Approvable Letter from FDA confirms that we are very close to PMA approval,' commented Olivier Taelman, Nyxoah's Chief Executive Officer. 'We believe the final remaining step is completing a process validation at our U.S. manufacturing site – action taken in response to the last set of specific validation questions sent by the FDA – which we are confident we can address swiftly and successfully. We look forward to launching Genio in the U.S. upon receipt of FDA approval.'
About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah's lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world's most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.
Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors' therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study.
For more information, please visit
http://www.nyxoah.com/
.
Caution
– CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States
FORWARD-LOOKING STATEMENTS
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah's goals with respect to the development, regulatory pathway and potential use of the Genio® system; receipt of FDA approval; satisfactory completion of a manufacturing facilities, methods and controls review, and the anticipated timing of the foregoing; entrance to the U.S. market; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the 'Risk Factors' section of the Company's Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on March 20, 2025, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
Contacts:
Nyxoah
John Landry, CFO
[email protected]
For Media
In United States
FINN Partners – Alyssa Paldo
[email protected]
In International/Germany
MC Services – Anne Hennecke
[email protected]
In Belgium/France
Backstage Communication – Gunther De Backer
[email protected]
Attachment
ENGLISH_Update on FDA Approvable Letter_FINAL
GlobeNewswire Distribution ID 1001078888
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gulf Insider
5 days ago
- Gulf Insider
COVID Vaccine Removed for Kids, Pregnant Women
On Tuesday, HHS Secretary Robert F. Kennedy Jr. delivered a historic course correction from the Biden-era vaccine alongside NIH Director Dr. Jay Bhattacharya and FDA Commissioner Dr. Marty Makary, Kennedy announced that COVID-19 vaccine recommendations for healthy children and pregnant women were officially removed from the CDC's immunization schedule. 'Hi, everybody. I'm Robert F. Kennedy, Jr., your HHS secretary. And I'm here today with NIH Director Dr. Jay Bhattacharya and FDA Commissioner Dr. Marty Makary. I couldn't be more pleased to announce that, as of today, the COVID vaccine for healthy children and healthy pregnant women has been removed from the CDC recommended immunization schedule.' It was an unmistakable shift away from coercive one-size-fits-all medicine, and a clear signal that data, not politics, is now leading the conversation. On Tuesday, HHS Secretary Robert F. Kennedy Jr. delivered a historic course correction from the Biden-era vaccine policy. Standing alongside NIH Director Dr. Jay Bhattacharya and FDA Commissioner Dr. Marty Makary, Kennedy announced that COVID-19 vaccine recommendations for… — The Vigilant Fox 🦊 (@VigilantFox) June 1, 2025 Today, Dr. Marty Makary took the fight straight into the lion's den—appearing on CBS to dismantle the network's go-to vaccine talking points. When host Margaret Brennan tried to paint the updated guidance as confusing, Makary didn't flinch. 'Can you clearly state what the policy is? Because this is confusing,' she asked. Makary responded without hesitation: 'Yeah, we believe the recommendation should be with a patient and their doctor.' That's when the real shift came into focus. 'So we're going to get away from these blanket recommendations in healthy young Americans.' 'On the COVID vaccine schedule, we don't want to see kids kicked out of school because a 12-year-old girl is not getting her fifth COVID booster shot.' 'We don't see the data there to support a young, healthy child getting a repeat infinite annual COVID vaccine.' He then laid out the sheer absurdity of where the old policy was heading. 'There's a theory that we should sort of blindly approve the new COVID boosters in young, healthy kids every year in perpetuity, and a young girl born today should get 80 COVID mRNA shots or other COVID shots in her average lifespan.' 'We're saying that's a theory, and we'd like to check in and get some randomized controlled data. It's been about four years since the original randomized trials. So we'd like an evidence based approach.' And then came the knockout line—delivered with facts no one could deny. 'That is a decision between a parent and their doctor—I don't know if you know these statistics, but 88% of American kids, their parents have said no to the COVID shot last season. So America, the vast majority of Americans are saying no.' Today, Dr. Marty Makary took the fight straight into the lion's den—appearing on CBS to dismantle the network's go-to vaccine talking host Margaret Brennan tried to paint the updated guidance as confusing, Makary didn't flinch.'Can you clearly state what the… — The Vigilant Fox 🦊 (@VigilantFox) June 1, 2025 Brennan tried to shift gears—falling back on CDC data to argue that even healthy kids remained at risk. 'So the CDC data said 41% of children aged 6 months to 17 years hospitalized with COVID between 2022 and 2024 did not have a known underlying condition. In other words, they looked healthy,' she said. 'And COVID was serious for them.' But Makary was ready. Calm and precise, he dismantled the claim with surgical clarity. 'So first of all, we know the CDC data is contaminated with a lot of false positives from incidental positive COVID tests with routine testing of every kid that walks in the hospital.' 'We know that data historically under the Biden administration did not distinguish being sick from COVID or an incidental positive COVID test.' He shared what he's heard from the people who actually run the ICUs in America. 'When you go to an ICU in America and you ask how many people are in the ICU that are healthy, that are sick with COVID? The answer I get again, again is we haven't seen that in a year or years.' That's why, he warned, making universal recommendations based on flawed data isn't just wrong—it's dangerous. 'And so the worst thing you can do in public health is to put out an absolute universal recommendation in young, healthy kids.' 'And the vast majority of Americans are saying, no, we want to see some data. And you say, forget about the data, just get it anyway.' Brennan tried to shift gears—falling back on CDC data to argue that even healthy kids remained at risk.'So the CDC data said 41% of children aged 6 months to 17 years hospitalized with COVID between 2022 and 2024 did not have a known underlying condition. In other words, they… — The Vigilant Fox 🦊 (@VigilantFox) June 1, 2025 But it was the final exchange that landed like a sledgehammer. When Brennan questioned why the HHS bypassed the CDC's Advisory Committee on Immunization Practices (ACIP) for the new policy shift, Makary landed a haymaker. 'That panel has been a kangaroo court where they just rubberstamp EVERY single vaccine put in front of them.' He said the committee hadn't been focused on science, but on messaging and marketing. 'You look at the minutes of the last couple of years, they say, we want a simple message for everybody just so they can understand it. It was not a data based conversation. It was a conversation based on marketing and ease.' And without real evidence, he warned, these recommendations become little more than guesswork. 'If there's zero clinical data, you're opining. I mean—it's a theory.' 'And so we don't want to put out an absolute recommendation for kids, with no clinical data to support it.' The implication was unmistakable: public health decisions should be based on evidence and transparency—not rubber stamps and slogans. For the first time in years, someone on national television was calling out the system. But it was the final exchange that landed like a Brennan questioned why the HHS bypassed the CDC's Advisory Committee on Immunization Practices (ACIP) for the new policy shift, Makary landed a haymaker.'That panel has been a kangaroo court where they just… — The Vigilant Fox 🦊 (@VigilantFox) June 1, 2025 Also read: Moderna Disables Comments On X Post Announcing New Covid Shot Amid Backlash
Gulf Insider
5 days ago
- Gulf Insider
Moderna Disables Comments On X Post Announcing New Covid Shot Amid Backlash
Moderna shares rose in premarket trading after the company announced FDA approval of its new lower-dose Covid-19 vaccine, mNEXSPIKE, for adults aged 65 and older, as well as individuals 12–64 with underlying health conditions. However, the approval sparked backlash on X, with many questioning the Trump administration and Health Secretary Robert F. Kennedy Jr.'s 'MAHA' (Make America Healthy Again) agenda. Moderna said in a Saturday morning X post that the mNEXSPIKE (mRNA-1283) vaccine should be available in the U.S. in time for the 2025-26 respiratory virus season, which starts later this year. 'The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19,' CEO Stéphane Bancel stated in a press release. Bancel noted, 'COVID-19 remains a serious public health threat, with more than 47,000 Americans dying from the virus last year alone. We appreciate the FDA's timely review and thank the entire Moderna team for their hard work and continued commitment to public health.' Last month, the FDA announced that Covid vaccines would not be offered this fall to healthy children and adults. At the same time, the Trump administration stated that any new Covid vaccines must undergo clinical trials using an inert placebo—such as saline—rather than being tested against existing approved vaccines. Moderna's X post was met with heavy backlash, as many users voiced outrage over the FDA's approval, under Health Secretary RFK Jr., of yet another round of Covid vaccines. Moderna's social media team disabled comments on the post. Bottom line: people are furious: X user KAS14599753: ' When your products are so safe and effective, you turn off the comments.' X user Dr Aseem Malhotra: ' Complete and total madness. This company ( like Pfizer ) should be under investigation.' X user Gadsden2020: ' Gee, I wonder why they don't let everyone comment on this? Could it be that they know people aren't buying their bullshit anymore? We know it's only about the $$$.' X user DocAhmadMalik: ' Thank you, Donald Trump, Bobby, Jay, and Aseem, for proving that you are in on the game or totally hopeless.' Click here to read more…
Gulf Insider
22-05-2025
- Gulf Insider
FDA No Longer Recommends COVID Vaccine For Healthy Babies
The U.S. government no longer recommends the COVID-19 vaccine for healthy babies thanks to new guidelines from the Trump administration, which said Tuesday it will limit approval for seasonal COVID-19 shots to seniors and others at high risk pending more data on everyone else. Top officials for the Food and Drug Administration laid out new standards for updated COVID shots, saying they'd continue to use a streamlined approach to make them available to adults 65 and older as well as children and younger adults with at least one high-risk health problem. But the FDA framework, published Tuesday in the New England Journal of Medicine, urges companies to conduct large, lengthy studies before tweaked vaccines can be approved for healthier people. Previously, federal policy recommended an annual COVID shot for all Americans six months and older. In the paper and a subsequent online webcast, the FDA's top vaccine official said more than 100 million Americans still should qualify for what he termed a booster under the new guidance. Dr. Vinay Prasad described the new approach as a 'reasonable compromise' that will allow vaccinations in high-risk groups to continue while generating new data about whether they still benefit healthier people. 'For many Americans we simply do not know the answer as to whether or not they should be getting the seventh or eighth or ninth or tenth COVID-19 booster,' said Prasad, who joined the FDA earlier this month. He previously spent more than a decade in academia, frequently criticizing the FDA's handling of drug and vaccine approvals. It's unclear what the upcoming changes mean for people who may still want a fall COVID-19 shot but don't clearly fit into one of the categories. Provisional data from the Centers for Disease Control and Prevention shows more than 47,000 Americans died from COVID-related causes last year. The virus was the underlying cause for two-thirds of those and it was a contributing factor for the rest. Health experts say there are legitimate questions about how much everyone still benefits from yearly COVID vaccination or whether they should be recommended only for people at increased risk. In June, an influential panel of advisers to the CDC is set to debate which vaccines should be recommended to which groups.
